Adverse lower gastrointestinal effects of non-selective and COX-2 selective NSAIDs: A systematic review

被引：0

|

作者：

Laine, Loren

Smith, Rebecca A.

Min, Kejia

Chen, Connie

Dubois, Robert W.

机构：

来源：

GASTROENTEROLOGY | 2006年 / 130卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：A303 / A304

页数：2

相关论文

共 50 条

[31] Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor
Yamamoto, T
NozakiTaguchi, N
BRAIN RESEARCH, 1996, 739 (1-2) : 104 - 110
[32] The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors
Laine, L
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2002, 32 (03) : 25 - 32
[33] COX-2 NSAIDs plus GI protective agents (GIPA) result in substantially lower ulcer ADR rates compared with non-selective NSAIDs plus GIPA.
Wolfe, F
Anderson, J
Burke, T
Arguelles, L
Pettitt, D
ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S225 - S225
[34] NSAIDs: gastroprotection or selective COX-2 inhibitors? Reply
Dickman, A
Ellershaw, J
PALLIATIVE MEDICINE, 2005, 19 (02) : 166 - 167
[35] Pharmacology and clinical action of COX-2 selective NSAIDs
Bovill, JG
ADVANCES IN MODELLING AND CLINICAL APPLICATION OF INTRAVENOUS ANAESTHESIA, 2003, 523 : 201 - 214
[36] Co-Prescription of Gastroprotective Agents in Patients Taking Non-Selective NSAIDs or COX-2 Selective Inhibitors: A Hospital Based Retrospective Study
Thobari, Jarir A. T.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 415 - 415
[37] Selective COX-2 inhibitors vs NSAIDs discussed
Reactions Weekly, 2002, 906 (1) : 3 - 3
[38] Bayesian Prescribing Model for Cox-2 Selective NSAIDS
Stedman, Margaret R.
Brookhart, M. A.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S31 - S32
[39] Will the promise of the COX-2 selective NSAIDs come to fruition?
不详
Drugs & Therapy Perspectives, 2001, 17 (11) : 6 - 10
[40] What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs
R Andrew Moore
Sheena Derry
Henry J McQuay
John Paling
Arthritis Research & Therapy, 10

← 1 2 3 4 5 →